Table 3 Antibody-drug conjugates in clinical trials for multiple myeloma
From: Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma
ADC names | Target | Linker | Payload | Disease | Major responses | Status [reference] |
|---|---|---|---|---|---|---|
Lorvotuzumab mertansine (IMGN901) | CD56 | Disulfide bond (SPP) | DM1 | R/R MM | ORR 5.7%, CR 0; 42.9% stable disease for 15.5 mo | Phase I [136] |
Milatuzumab doxorubicin (hLL1-DOX) | CD74 | Acid-labile (hydrazine) | Doxorubicin | R/R MM | Data not reported | Phase I [137] |
Indatuximab ravtansine (BT062) | CD138 | Disulfide bond (SPDB) | DM4 | R/R MM | ORR 5.9%, CR 0, stable disease 61.8%, OS 26.7 mo, PFS 3 mo | Phase I/II [138] |
GSK2857916 | CD269 (BCMA) | Non-cleavable (MC) | MMAF | R/R MM | ORR 60%, CR 14%, PFS 12 mo, DOR 14.3 mo | Phase I [139] |